16 completed, 3 not yet recruiting, 3 recruiting, 2 unknown. 27 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 27 | Completed 16, Not yet recruiting 3, Recruiting 3, Unknown 2, Withdrawn 2, Terminated 1 |
| Phase 2 | 6 | Completed 3, Recruiting 1, Terminated 1, Unknown 1 |
Follow Plaque, Amyloid: new trials by email Literature Review of Plaque, Amyloid trials Research Report on Plaque, Amyloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD) LY4560736, Placebo, Florbetapir F18 - Healthy Volunteers, Alzheimer Disease | Phase 1 | Not yet recruiting | Eli Lilly and Company | 111 | 2026-10-01 | 2026-10-08 |
| Phase 1 Study to Evaluate the Safety and Tolerability of 8M2D in Healthy People and Alzheimer's Patients 8M2D, Placebo - Alzheimer's Disease (AD) | Phase 1 | Not yet recruiting | Cenna Biosciences Inc. | 54 | 2026-09-15 | 2026-05-05 |
| A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease LY4405094, Placebo, Florbetapir F18 - Alzheimer Disease, Amyloid | Phase 1 | Recruiting | Eli Lilly and Company | 179 | 2026-09-09 | 2026-11-05 |
| Prospective Single-Arm Safety Study of Cervical LVA in AD Patients Supermicrosurgical Lymphaticovenular Anastomosis (LVA) - Alzheimer's Disease (AD) | Phase 1 | Not yet recruiting | Chang Gung Memorial Hospital | 35 | 2026-03-01 | 2026-03-09 |
| A Clinical Trial to Study Single- and Multiple- Doses of GSM-779690T in Healthy Participants GSM-779690T, Placebo - Healthy Adult Participants | Phase 1 | Withdrawn | Acta Pharmaceuticals | 2025-11-09 | 2026-01-07 | |
| A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease LY4405094, Placebo, Florbetapir F18 - Healthy Volunteers, Alzheimer Disease | Phase 1 | Recruiting | Eli Lilly and Company | 68 | 2025-10-14 | 2026-10-22 |
| Propolis Lozenges Extract and Their Effect on Salivary Biomarkers and on Oral Health Condition in (19_24) Years Old lozenges containing propolis - Plaque Induced Gingivitis, Mouth Diseases | Phase 1 | Completed | Al-Mustansiriyah University | 100 | 2025-03-23 | 2025-09-24 |
| A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a - Amyloid Plaque, Beta-Amyloid | Phase 1 / Phase 2 | Recruiting | AC Immune SA | 304 | 2022-06-21 | 2026-07-10 |
| Convalescent Plasma Therapy in Patients With COVID-19 Convalescent plasma - Convalescence, Corona Virus Infection | Phase 1 | Completed | Biofarma | 10 | 2020-05-01 | 2020-06-30 |
| Six Week Study of Experimental Mouth Rinses: Effect on Gingivitis and Plaque Colgate® Cavity Protection Toothpaste, Listerine® Cool Mint®, Concept Curve Winter Series Toothbrush - Gingivitis, Plaque | Phase 1 | Completed | Johnson & Johnson Consumer Inc. (J&JCI) | 157 | 2019-10-08 | 2023-09-28 |
| Blood Brain Barrier Opening in Alzheimer' Disease SONOCLOUD® - Alzheimer Disease | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 10 | 2017-06-26 | 2022-04-12 |
| Evaluation of Periodontal Response to Non Surgical Therapy in Pre and Post Menopausal Women With Periodontitis scaling and root planing (srp) - Periodontitis, Menopause | Phase 1 / Phase 2 | Completed | Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre | 60 | 2015-01-01 | 2016-03-24 |
| Evaluate the Effect of Elimune Capsules Elimune Capsules - Plaque Psoriasis | Phase 1 | Completed | Elorac, Inc. | 21 | 2014-09-01 | 2015-12-08 |
| A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis PF06263276, Vehicle, 2%Tofacitinib Ointment - Psoriasis Vulgaris | Phase 1 | Completed | Pfizer | 15 | 2014-09-01 | 2016-06-09 |
| A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects Bexarotene, Placebo - Alzheimer's Disease | Phase 1 | Completed | ReXceptor, Inc. | 12 | 2014-08-01 | 2015-08-13 |
| Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population 2 mg KSL-W, 4 mg KSL-W, 6 mg KSL-W - Plaque, Gingivitis | Phase 1 / Phase 2 | Completed | U.S. Army Medical Research and Development Command | 135 | 2014-02-25 | 2020-02-13 |
| Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration - Atrophy, Geographic | Phase 1 | Completed | GlaxoSmithKline | 36 | 2014-01-22 | 2017-05-15 |
| Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study DD-25 - Psoriasis Vulgaris | Phase 1 / Phase 2 | Unknown | Fortuderm Ltd. | 30 | 2012-10-01 | 2012-10-08 |
| An Open Positron Emission Tomography Study to Assess the Effects of Varying Mass of AZD4694 on Radioligand Binding Parameters in Healthy Volunteers and Patients With Alzheimer's Disease [18Fluor]AZD4694 - Maximum Diagnostic Mass of [18Fluor]AZD4694 | Phase 1 | Completed | AstraZeneca | 16 | 2011-08-01 | 2012-12-10 |
| Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F) SNUBH-NM-333(18F) - Alzheimer Disease | Phase 1 / Phase 2 | Terminated | Seoul National University Hospital | 30 | 2010-12-01 | 2014-05-29 |
Showing 20 of 27. Sign in to see all of them.
Alzheimer Disease (13) · Gingivitis (4) · Psoriasis (3) · Dementia (2) · Arteriosclerosis (1) · Brain Diseases (1) · COVID-19 (1) · Central Nervous System Diseases (1) · Convalescence (1) · Coronary Artery Disease (1) · Coronavirus Infections (1) · Down Syndrome (1) · Frontotemporal Dementia (1) · Geographic Atrophy (1)
Pathological Conditions, Anatomical (27) · Pathological Conditions, Signs and Symptoms (27) · Mental Disorders (13) · Nervous System Diseases (13) · Neurocognitive Disorders (13) · Tauopathies (13) · Brain Diseases (12) · Central Nervous System Diseases (12) · Neurodegenerative Diseases (12) · Dementia (11) · Infections (5) · Stomatognathic Diseases (5) · Gingival Diseases (4) · Mouth Diseases (4) · Periodontal Diseases (4)
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (4) · florbetapir (3) · AZD2995 (1) · Bexarotene (1) · Fluorides (1) · Organization and Administration (1) · PF-06263276 (1) · Propolis (1) · Root Planing (1) · Silicon Dioxide (1) · Tooth Exfoliation (1) · Urocortins (1) · calcipotriene (1) · tofacitinib (1)
Eli Lilly and Company (3) · AstraZeneca (2) · GlaxoSmithKline (2) · Pfizer (2) · AC Immune SA (1) · Acta Pharmaceuticals (1) · Al-Mustansiriyah University (1) · Assistance Publique - Hôpitaux de Paris (1) · Biofarma (1) · Cenna Biosciences Inc. (1) · Chang Gung Memorial Hospital (1) · Elorac, Inc. (1) · Fortuderm Ltd. (1) · GAAD Medical Research Institute Inc. (1) · Johnson & Johnson Consumer Inc. (J&JCI) (1)
United States (12) · China (3) · Japan (3) · Sweden (2) · Taiwan (2) · Australia (1) · Canada (1) · France (1) · Germany (1) · Indonesia (1) · Iraq (1) · Israel (1) · South Korea (1) · Spain (1) · United Kingdom (1)
Bjorn Paulsson (1) · Craig T Curtis, MD (1) · Domenick T Zero, DDS, MS (1) · Doug Galasko, MD (1) · Elisabeth Eden, MD (1) · Emma Gyllenpalm (1) · Hagit Matz, M.D. (1) · Jeffery Milleman, DDS (1) · Ken Nedd, M.D. (1) · Kwasi Donyina, Ph.D. (1)
PMID 24970906, PMID 29067298, PMID 33773598, PMID 34104878, PMID 3425152, PMID 34815790, PMID 35260178, PMID 3793432, PMID 38762482, PMID 39466933
2014 (1), 2016 (1)